Abstract 708: Clinical significance of insulin-like growth factor 1 receptor (IGF1R) expression in pancreatic cancer

Abstract

Abstract Introduction: Insulin like growth factor 1 receptor (IGF1R) reported to be overexpressed in some types of human carcinomas, including lung cancer, and breast cancer. However no report of the significance of IGF1R expression was available in pancreatic cancer. Most patients with pancreatic cancer die within 2 years at diagnosis even after curative resection. The objective of this study was to evaluate the significance of IGF1R expression in human pancreatic cancer. Material and Methods: A total 122 patients with pancreatic cancer was studied. Paraffin embedded species of pancreatic cancers were stained with antibodies against IGF1R. IGF1R expression was evaluated by intensity of staining. Semi-quantitative scores of zero (no staining), 1+ (weak staining), 2+ (moderate staining), or 3+ (strong staining) were assigned to each sample based on the intensity of staining. Scores of 2+ or 3+ were defined as IGF1R-positive staining. The association between IGF1R expression and clinicopathologic variables was examined. Results: IGF1R expression was positive in 50 (40.1%) of 122 cases. Kaplan-Meier analysis demonstrated the prognosis of IGF1R-positive patients was significantly (p=0.0076) poorer than that of IGF1R-negative, and median survival time of patients with IGF1R-positive was 37.3 months, while that of patients with IGF1R-negative samples was 60.8 months. There were no associations between IGF1R overexpression and clinicopathological factors, including tumor location, tumor size, tumor differentiation, and T/N categories according to the International Union against Cancer. Multivariate analysis showed IGF1R expression and lymph node metastasis were independent predictors of worse prognosis in pancreatic cancer. Conclusion: The expression of IGF1R might be a novel predictive prognostic marker for patients with pancreatic cancers. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 708. doi:1538-7445.AM2012-708